Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096096 · ClinicalTrials.gov registry record · Phase 2
Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00096096: Completed Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
NCT00096096 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00096096, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Tacrolimus and mycophenolate mofetil may be an effective treatment for graft-versus-host disease caused by donor stem cell transplantation. PURPOSE: This phase II trial is studying how well giving tacrolimus together with mycophenolate mofetil works in preventing acute graft-versus-host disease in patients who are undergoing donor stem cell transplantation for advanced hematologic cancer.
Interventions
- DRUG tacrolimus
- DRUG mycophenolate mofetil
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-08 |
| Phase | Phase 2 |
What the finished NCT00096096 record still lists
NCT00096096 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which tacrolimus is the first listed.
NCT00096096 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00096096 about?
NCT00096096 is a clinical study titled "Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation". RATIONALE: Tacrolimus and mycophenolate mofetil may be an effective treatment for graft-versus-host disease caused by donor stem cell transplantation. PURPOSE: This phase II trial is studying how well giving tacrolimus together with mycophenolate mofetil works in preventing acute graft-versus-host ...
What is the current status of trial NCT00096096?
This trial is currently completed. It is a Phase 2 study. The study started on 2004-08.
What interventions are being tested in trial NCT00096096?
The interventions under investigation include: tacrolimus (DRUG), mycophenolate mofetil (DRUG).
Who is sponsoring clinical trial NCT00096096?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia